Poster Presentations Session II
Poster Presentations Session II Monday, May 18, 2015
POSTERS SET-UP: 3:30 PM - 3:45 PM
POSTERS DISPLAY HOURS: 3:45 PM - 7:45 PM
POSTER AUTHOR DISCUSSION: 6:45 PM - 7:45 PM
POSTERS DISMANTLE: 7:45 PM


Poster display locations are shown below the poster codes
HEALTH CARE USE & POLICY STUDIES - Consumer Role in Health Care
PHP1
A1
ASSOCIATION BETWEEN INFORMAL CAREGIVERS' ASSISTANCE IN MANAGEMENT OF CARE-RECIPIENTS' MEDICATIONS AND THEIR USE OF TRAINING SERVICES-A NATIONAL RETROSPECTIVE STUDY
Noureldin M1, Murawski M2, Mason H2, Hyner G3, Plake K1
1Purdue University College of Pharmacy and Center on Aging and the Life Course, West Lafayette, IN, USA, 2Purdue University College of Pharmacy, West Lafayette, IN, USA, 3Purdue University College of Health and Human Sciences and Center on Aging and the Life Course, West Lafayette, IN, USA

PHP2
A2
PATIENTS SENT TO THE EMERGENCY DEPARTMENT BY ADVANCED HEALTHCARE PROVIDERS ARE MORE LIKELY TO NEED ADMISSION
Groner K1, Lange CE1, Davis B1, Bounds RB2
1Christiana Care Health System, Newark, DE, USA, 2Sidney Kimmel Medical College, Philadelphia, PA, USA

HEALTH CARE USE & POLICY STUDIES - Diagnosis Related Group
PHP3
A3
THE EFFECT OF DRG-BASED PERFORMANCE- VOLUME LIMIT ON THE ANNUAL BUDGET OF THE CLINICAL CENTRE OF UNIVERSITY OF PÉCS IN HUNGARY
Endrei D1, Ágoston I1, Csákvári T2, Répásy B1, Molics B1, Danku N1, Vajda R1, Boncz I1
1University of Pécs, Pécs, Hungary, 2University of Pécs, Zalaegerszeg, Hungary

HEALTH CARE USE & POLICY STUDIES - Disease Management
PHP4
A4
PREVENTABLE HOSPITALIZATIONS AMONG WEST VIRGINIA MEDICAID BENEFICIARIES WITH CHRONIC CONDITIONS
Agarwal P, Bose S, Bias T, Sambamoorthi U
West Virginia University, Morgantown, WV, USA

PHP5
A5
PREPARATION OF A DATASET FOR ANALYSIS TO DEVELOP A PREDICTOR ALGORITHM FOR DISEASE STATE MANAGEMENT
Lovett AW1, Chaturvedula A2, Mukherjee K2, Brar A2, Tamhankar N2
1Mercer University, Atlanta, GA, USA, 2GVK Biosciences, Hyderabad, India

PHP6
A6
DISPARITES IN PATIENT RESPONSE TO POTENTIAL ADVERSE DRUG EFFECT
Ning N1, Lu Y2, Gascue L1, Ding Y1, Joyce G1
1University of Southern California, Los Angeles, CA, USA, 2Harbor-UCLA Medical Center, Torrance, CA, USA

PHP7
A7
PATIENT AWARENESS AND USE OF MEDICATION GUIDES
Walton A1, Paul K2
1United BioSource Corporation, Blue Bell, PA, USA, 2The Corvallis Group, LLC, Summit, NJ, USA

PHP8
A8
PERCEPTIONS OF COMMUNITY PHARMACISTS ABOUT THEIR CURRENT PROFESSIONAL ROLE, INTER PROFESSIONAL LEARNING AND CONTINUE PROFESSIONAL DEVELOPMENT IN PAKISTAN
Iqbal MS1, Iqbal MZ2, Iqbal MW3, Ping NY4, Bahari MB4
1Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan. Department of Clinical Pharmacy, Faculty of Pharmacy, MAHSA University, Selangor, Malaysia, 2Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Pulau Pinang, Malaysia Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia, 3Faculty of Law, University of Malaya, Kualalumpur, Malaysia, 4Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia

PHP9
A9
KNOWLEDGE, ATTITUDE AND PERCEPTIONS OF HOSPITAL PHARMACISTS TOWARDS PHARMACISTS LED INTERVENTIONS TO REDUCE ADVERSE DRUG REACTIONS, DRUG INTERACTIONS, AND PHARMACEUTICAL CARE ISSUES TOWARDS BETTER PHARMACEUTICAL CARE PLANNING: A QUALITATIVE INSIGHT FROM PAKISTAN
Iqbal MS1, Iqbal MW2, Iqbal MZ3, Akhtar N4, Ping NY3, Bahari MB3
1Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan. Department of Clinical Pharmacy, Faculty of Pharmacy, MAHSA University, Selangor, Malaysia, 2Faculty of Law, University of Malaya, Kualalumpur, Malaysia, 3Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia, 4Faculty of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur, Pakistan

HEALTH CARE USE & POLICY STUDIES - Drug/Device/Diagnostic Use & Policy
PHP10
A10
TRACKING THE SPONSORING COUNTRY OF INCORPORATION FOR NEW DRUGS APPROVED BY THE US FDA IN THE PERIOD 1980-2014: A TREND ANALYSIS
Alqahtani SS1, Rodriguez-Monguio R2, Seoane-Vazquez E1, Eguale T3, Zeukeng M4, Szeinbach S5
1MCPHS University, Boston, MA, USA, 2University of Massachusetts, Amherst, Amherst, MA, USA, 3Brigham and Women's Hospital, Boston, MA, USA, 4University of Geneva, Geneva, Switzerland, 5Ohio State University, Columbus, OH, USA

PHP11
WITHDRAWN

PHP12
A11
THE IMPACT OF THE ESSENTIAL MEDICINE POLICY ON PATIENTS' HEALTH CARE UTILIZATION AND COST IN TIANJIN CHINA: A QUASI-EXPERIMENTAL DESIGN
Ding L, Wu J
Tianjin University, Tianjin, China

PHP13
WITHDRAWN

PHP14
A12
IMPACT OF 2014 ESSENTIAL HEALTH BENEFIT BENCHMARK PLANS ON US MANAGED CARE
Aggarwal S, Topaloglu H
NOVEL Health Strategies, Chevy Chase, MD, USA

PHP15
A13
AN ASSESSMENT OF THE THERAPEUTIC BIOLOGIC PRODUCTS LICENSED BY THE FDA AND THE EMA
Grozdanova A1, Olasupo O2, Seoane-Vazquez E3
1Faculty of Pharmacy UKIM, Skopje Macedonia, Skopje, Macedonia, 2Massachusetts College of Pharmacy & Health Sciences, Boston, MA, USA, 3MCPHS University, Boston, MA, USA

PHP16
WITHDRAWN

PHP17
A14
THE IMPACT OF NEW DRUG PRICING POLICY ON MARKET COMPETITION AMONG OFF-PATENT DRUGS IN SOUTH KOREA
Kwon H1, Kim H2, R. Reich M1
1Harvard T.H. Chan School of Public Health, Boston, MA, USA, 2National Health Insurance Service, Seoul, South Korea

PHP18
A15
THE ROLE OF COST-EFFECTIVENESS STUDIES IN DRUG PRICING DECISIONS: A CASE REVIEW FROM JORDAN
Hammad E1, Obeidat HM2, Hadidi I2, Batarseh S2, Al-Efan QM3
1University of Jordan, Amman, Jordan, 2Jordan food and Drug Association, Amman, Jordan, 3Jordan University of Science & Technology, Irbid, Jordan

PHP19
A16
THE DIFFERENCE BETWEEN THE MAXIMUM RETAIL PRICE AND TENDER PRICE: A COMPARATIVE STUDY ON BRANDNAME AND GENERIC DRUGS
Liu B
Department of Health Economics, School of Public Health, Fudan University, Shanghai, China

PHP20
A17
ANALYSIS OF THE DRUG PRICE REVIEWS PERFORMED BY THE CANADIAN PATENTED MEDICINE PRICES REVIEW BOARD (1998-2014)
Alsumali A1, Seoane-Vazquez E2, Eguale T3, Mekary R3
1MCPHS University, Brighton, MA, USA, 2MCPHS University, Boston, MA, USA, 3MCPHS University, N/A, MA, USA

PHP21
A18
CHANGES OF THE HUNGARIAN HEALTH INSURANCE PHARMACEUTICAL BUDGET BETWEEN 2007-2013
Boncz I1, Ágoston I1, Csákvári T2, Vajda R1, Molics B1, Oláh A1, Danku N1, Répásy B1, Endrei D1
1University of Pécs, Pécs, Hungary, 2University of Pécs, Zalaegerszeg, Hungary

PHP22
A19
EFFECT OF THE U.S.-PERU FREE TRADE AGREEMENT ON PERUVIAN NEW DRUG POLICIES AND THE REGISTRATION OF PHARMACEUTICAL PRODUCTS
Araujo LE, Montagne M
MCPHS University, Boston, MA, USA

PHP23
A20
THE CHARACTERISTICS OF PHARMACY AND THERAPEUTIC COMMITTEES IN SAUDI HOSPITALS
Alkelya M1, Alenezi MG2, Alsultan MM2, AlJeraisy M3
1King Abdullah International Medical Research Center (KAIMRC), Ryiadh, Saudi Arabia, 2King Saud University, Riyadh, Saudi Arabia, 3King Saud Bin Abdulaziz University for Health Sciences (KSAU-HS), Ryiadh, Saudi Arabia

PHP24
A21
PRINCIPLES OF POLICY FRAMEWORK IN THE PHARMACEUTICAL WHOLESALE AND RETAIL SYSTEM IN LOWER INCOME EUROPEAN COUNTRIES
Inotai A1, Csanadi M1, Hanko B2, Kalo Z3
1Syreon Research Institute, Budapest, Hungary, 2Semmelweis University Faculty of Pharmacy, Budapest, Hungary, 3Eötvös Loránd University, Faculty of Social Sciences, Budapest, Hungary

PHP25
B1
ORPHAN AND ULTRA-ORPHAN TECHNOLOGIES IN THE NEW ERA OF PAYMENT REFORM: UNITED STATES PAYER PERCEPTIONS
Hogue S1, Brogan AP2, Croft E3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2RTI-Health Solutions, Research Triangle Park, NC, USA, 3RTI-Health Solutions, Manchester, UK

PHP26
B2
BREAKTHROUGH THERAPY STATUS – EXPEDITED FDA REGULATORY APPROVAL BUT WHAT ABOUT THE PAYERS?
Macaulay R1, Cost P2
1PAREXEL, London, UK, 2PAREXEL, East Windsor, NJ, USA

PHP27
B3
A NECESSARY CONVERGENCE? US PAYERS ADOPTING EU BEHAVIORS
Macaulay R, Hempshall P
PAREXEL, London, UK

PHP28
B4
UNITED STATES DECISION MAKER PERCEPTIONS OF DATA FROM OBSERVATIONAL STUDIES AND OTHER HEALTH ECONOMICS AND OUTCOMES RESEARCH
Brogan AP1, Hogue S1, Mordin M2, Kwong J3
1RTI Health Solutions, Research Triangle Park, NC, USA, 2RTI Health Solutions, Ann Arbor, MI, USA, 3Daiichi Sankyo, Parsippany, NJ, USA

PHP29
B5
EVIDENCE THAT WEREWOLVES AFFECT THE NICE APPRAISAL PROCESS
Macaulay R1, Cost P2
1PAREXEL, London, UK, 2PAREXEL, East Windsor, NJ, USA

PHP30
B6
CHARACTERISTICS OF NURSING ASSOCIATED WITH COMPLETION OF COMPLIANCE MONITORING PROGRAM FOR SUBSTANCE ABUSE
Bhounsule P1, Moes S2, Peterson AM3
1University of the Sciences in Philadelphia, Philadelphia, PA, USA, 2Livengrin Foundation, Inc., Bensalem, PA, USA, 3University of the Sciences, Philadelphia, PA, USA

PHP31
B7
FDA BREAKTHROUGH THERAPY STATUS - A SYSTEMATIC ANALYSIS OF ALL THERAPIES APPROVED UNDER THIS NEW EXPEDITED APPROVAL PATHWAY
Macaulay R
PAREXEL, London, UK

PHP32
B8
PROFILE OF DEMANDED MEDICINES AND INFLUENCE OF INTELLECTUAL PROPERTY RIGHTS PROTECTION IN MINAS GERAIS, BRAZIL
Nascimento RC1, Guerra Junior AA1, Silva RL2
1College of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil, 2Law School, Federal University of Minas Gerais, Belo Horizonte, Brazil

PHP33
B9
COMPETITION AND STRATEGIC REGULATION IN THE ARGENTINE PHARMACEUTICAL MARKET. A COMPARATIVE STUDY OF SIX THERAPEUTIC CLASSES
Maceira D, Palacios A
Center for the Study of State and Society (CEDES), Buenos Aires, Argentina

PHP34
B10
AN ANALYSIS OF WARNING LETTERS ISSUED TO PHARMACEUTICAL COMPANIES REGARDING MISLEADING HEALTH OUTCOMES CLAIMS 2009-2013
Lionnet L, Fader A
MedVal Scientific Information Services, Skillman, NJ, USA

PHP35
B11
CHARACTERISTICS OF PRODUCTS WITH PRICE CHANGES AFTER A POLICY CHANGE IN EGYPT
Mohamed O1, Kreling D2
1Merck & Co. Inc., Lebanon, NJ, USA, 2School of Pharmacy, Madison, WI, USA

PHP36
WITHDRAWN

PHP37
B12
A FRAMEWORK FOR STRENGTHENING PHARMACEUTICAL MANUFACTURING IN SUB-SAHARAN AFRICA
Mann M1, Adamson BJ1, Rennie T2, Stergachis A1
1University of Washington, Seattle, WA, USA, 2University of Namibia, Windhoek, Namibia

PHP38
B13
DEVELOPING ALGORITHMS FOR IDENTIFYING BENEFICIARIES WITH HIGHER THAN EXPECTED UTILIZATION OF OPIOIDS ANALGESICS
Verma D1, Banahan III B2, Hardwick SP3, Clark JP3
1University of Mississippi, Oxford, MS, USA, 2University of Mississippi, University, MS, USA, 3Mississippi Division of Medicaid, Jackson, MS, USA

PHP39
B14
THE USE OF PHARMACY CLAIMS DATA AS AN EARLY INDICATOR OF BIOEQUIVALENCE ISSUES FOR NEWLY LAUNCHED GENERIC MEDICATIONS
Levin R1, Cosmatos I1, Germscheid LM1, Frazee S2, Dieck G1, Murray R1, Patel A1, Henderson R2
1United BioSource Corporation, Blue Bell, PA, USA, 2Express Scripts, St. Louis, MO, USA

PHP40
B15
FEDERAL EXCHANGES PROVIDE LOWER PREMIUMS BUT LESS GENEROUS PHARMACY BENEFITS THAN EMPLOYER-SPONSORED PLANS
Buttorff C1, Andersen MS2, Riggs K3, Chen Y4, Alexander GC4
1RAND, Arlington, VA, USA, 2University of North Carolina, Greensboro, NC, USA, 3Johns Hopkins Medical Institutions, Baltimore, MD, USA, 4Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

PHP41
B16
SUBSTANCE USE ADMISSIONS TREND AMONG OLDER ADULTS
Chhatre S, Metzger DS, Jayadevappa R
University of Pennsylvania, Philadelphia, PA, USA

PHP42
B17
ANTIMICROBIAL UTILISATION IN SLOVAK HOSPITALS
Snopkova M1, Antlova K1, Majtas J2
1Faculty of Pharmacy Comenius University, Bratislava, Slovak Republic, 2Comenius University, Bratislava, Slovak Republic

PHP43
B18
DRUG RELATED PROBLEMS, PRESCRIBING PATTERN AND POLYPHARMACY: EVIDENCE FROM COMMUNITY PHARMACIES IN PAKISTAN
Iqbal MS1, Iqbal MZ2, Iqbal MW3, Akhtar N4, Bahari MB5
1Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan. Department of Clinical Pharmacy, Faculty of Pharmacy, MAHSA University, Selangor, Malaysia, 2Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Pulau Pinang, Malaysia Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia, 3Faculty of Law, University of Malaya, Kualalumpur, Malaysia, 4Faculty of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur, Pakistan, 5Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia

PHP44
B19
PATIENTS' PERCEPTION AND KNOWLEDGE OF ADVERSE DRUG REACTIONS ASSOCIATED WITH HERBAL MEDICINES
Bhat B, Dharmagadda S, Nayanabhirama U
Manipal University, Manipal, India

HEALTH CARE USE & POLICY STUDIES - Equity and Access
PHP45
B20
IMPACT OF MEDICAID MANAGED CARE EXPANSION ON ACCESS TO PROVIDERS IN MISSISSIPPI
Shahpurwala Z1, Ramachandran S1, Banahan III B1, Hardwick SP2, Clark JP2
1University of Mississippi, University, MS, USA, 2Mississippi Division of Medicaid, Jackson, MS, USA

PHP46
B21
GEOGRAPHICAL ACCESSIBILITY TO COMMUNITY AND HOSPITAL PHARMACIES IN HAMILTON COUNTY
Gangal NS, Widener M, Kelton C, Heaton PC
University of Cincinnati, Cincinnati, OH, USA

PHP47
C1
ANALYSIS OF MEDICINES CENTRALLY AUTHORISED BY THE EUROPEAN MEDICINES AGENCY (EMA) IN THE CONTEXT OF THEIR REIMBURSEMENT IN POLAND
Sujkowska G, Jagodzinska-Kalinowska K, Matusewicz W, Zabielska J
Agency for Health Technology Assessment and Tariff System, Warsaw, Poland

PHP48
C2
ARE WE REALLY MEASURING ACCESS? SYSTEMATIC REVIEW OF ACCESS MEASURES TO MEDICINES IN BRAZIL
Araujo VE, Izidoro JB, Guerra-Junior Aa, Dias CZ, Ascef BO, Costa CM, Nascimento RC, Acurcio Fa, Alvares J
College of Pharmacy, Federal University of Minas Gerais, Belo Horizonte, Brazil

PHP49
C3
ACOUNTABLE CARE ORGANIZATIONS- AN ECONOMIC SOLUTION TO PROVIDE QUALITY HEALTHCARE FOR MEDICARE PATIENTS
Patel PH
University of the Sciences, philadelphia, PA, USA

PHP50
C4
ASSESSING THE AVAILABILITY OF DRUGS MARKETED IN THE US AND SWITZERLAND
Zeukeng M1, Seoane-Vazquez E2, Szeinbach S3
1University of Geneva, Geneva, Switzerland, 2MCPHS University, Boston, MA, USA, 3Ohio State University, Columbus, OH, USA

PHP51
C5
EVALUATION OF AUDIT SCORING CONSISTENCY IN A COMPREHENSIVE FEEDLOT MANAGEMENT SYSTEM AND CORRELATION WITH FEEDYARD PERFORMANCE BASED ON AVERAGE DAILY GAIN AND DRY FEED CONVERSION IN 11 US FEEDLOTS
Bouwer A1, Walter S2, Holland R3
1Zoetis LLC, Florham Park, NJ, USA, 2PCC Feedlot Investment Services Inc., Hydro, OK, USA, 3Zoetis, Florham Park, NJ, USA

PHP52
C6
ALL-CAUSE 30-DAY READMISSIONS AMONG MEDICAID BENEFICIARIES WITH SELECTED CHRONIC CONDITIONS: A MULTI-LEVEL ANALYSIS
Chopra I1, Wilkins TL2, Sambamoorthi U1
1West Virginia University, Morgantown, WV, USA, 2Office of the National Coordinator for Health Information Technology, Washington, DC, USA

PHP53
C7
FACTORS ASSOCIATED WITH ELECTRONIC HEALTH RECORD IMPLEMENTATION AMONG HOSPITALS IN AMERICAL HOSPITAL ASSOCIATION ANNUAL SURVEY DATABASE
Bhounsule P1, Peterson AM2
1University of the Sciences in Philadelphia, Philadelphia, PA, USA, 2University of the Sciences, Philadelphia, PA, USA

PHP54
C8
EFFICIENCY ANALYSIS OF THE HUNGARIAN OUTPATIENT-CARE SYSTEM WITH DATA ENVELOPMENT ANALYSIS
Csákvári T1, Turcsányi K1, Gyuró M2, Danku N2, Vajda R2, Ágoston I2, Boncz I2
1University of Pécs, Zalaegerszeg, Hungary, 2University of Pécs, Pécs, Hungary

HEALTH CARE USE & POLICY STUDIES - Formulary Development
PHP55
C9
IMPACT OF COST SHARING INCREASES UNDER PART D SPECIALTY TIERS ON BIOLOGIC ADHERENCE AND DISCONTINUATION AMONG MEDICARE BENEFICIARIES WITH MULTIPLE SCLEROSIS OR RHEUMATOID ARTHRITIS
Li P1, Hu T1, Yu X1, Chahin S2, Dahodwala NA1, Doshi JA1
1University of Pennsylvania, Philadelphia, PA, USA, 2University of Pennsylvania Health System, Philadelphia, PA, USA

PHP56
C10
ASSESSING THE GENEROSITY OF DRUG COVERAGE IN THE HEALTH INSURANCE EXCHANGES
Andersen MS1, Buttorff C2, Riggs K3, Alexander GC4
1University of North Carolina, Greensboro, NC, USA, 2RAND, Arlington, VA, USA, 3Johns Hopkins Medical Institutions, Baltimore, MD, USA, 4Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

PHP57
C11
THE UPTAKE OF BIOSIMILAR PRODUCTS BY BRITISH FORMULARIES
Alnahar S, Elliott R, Smith M
University of Nottingham, Nottingham, UK

PHP58
C12
IMPACT OF COST SHARING ON SPECIALTY DRUG UTILIZATION AND OUTCOMES: A REVIEW OF THE EVIDENCE AND FUTURE DIRECTIONS
Doshi JA1, Li P1, Ladage VP1, Taylor EA2
1University of Pennsylvania, Philadelphia, PA, USA, 2RAND Corporation, Santa Monica, CA, USA

PHP59
C13
WHEN IS HEALTH ECONOMICS AND OUTCOMES RESEARCH EVIDENCE IMPORTANT TO U.S. PAYERS?
Bajaj PS1, Willke RJ2, Basu A1, Sullivan SD1, Garrison LP1
1University of Washington, Seattle, WA, USA, 2Pfizer, Inc., New York, NY, USA

PHP60
C14
THE CALIFORNIAN TECHNOLOGY ASSESSMENT FORUM – THE ARRIVAL OF COST-UTILITY APPRAISALS OF DRUGS IN THE USA?
Macaulay R, Mistry J
PAREXEL, London, UK

HEALTH CARE USE & POLICY STUDIES - Health Care Costs & Management
PHP61
C15
HEALTHCARE RESOURCE UTILIZATION AMONG HISPANIC ADULTS RELATIVE TO NON-HISPANIC WHITE ADULTS IN THE US
Hopps M, Udall M, Makinson G, McDonald M, Mardekian J
Pfizer Inc., New York, NY, USA

PHP62
C16
POTENTIAL SAVINGS FROM A 15-DAY INITIAL FILL POLICY FOR SELECTED OUTPATIENT MEDICATIONS IN A STATE MEDICAID PROGRAM
Shahpurwala Z1, Ramachandran S1, Banahan III B1, Hardwick SP2, Clark JP2
1University of Mississippi, University, MS, USA, 2Mississippi Division of Medicaid, Jackson, MS, USA

PHP63
D1
EVALUATING THE COST OF PATIENT-CENTERED MEDICAL HOME TRANSFORMATION IN SMALL PRIMARY CARE PRACTICES
Vegesna A, Lieberthal RD, Payton C, Sarfaty M, Valko G
Thomas Jefferson University, Philadelphia, PA, USA

PHP64
D2
A SYSTEMATIC REVIEW OF COST-EFFECTIVENESS ANALYSIS (CEA) STUDIES FROM THE PATIENT'S PERSPECTIVE
Tai BB1, Bae YH2, Le Q2
1Khoo Teck Puat Hospital (Alexandra Health Pte Ltd), Singapore, Singapore, 2WESTERN UNIVERSITY OF HEALTH SCIENCES, POMONA, CA, USA

PHP65
D3
EFFECT OF PATIENT'S COST SHARING ON EXPENDITURES: AN INSTRUMENTAL VARIABLES APPROACH
Kawatkar AA
Kaiser Permanente Southern California, Pasadena, CA, USA

PHP66
D4
ECONOMIC IMPACT OF WASTE IN PRESCRIBING, DISPENSING, AND MEDICATION CONSUMPTION IN THE UNITED STATES
Almanie SA, Holdford DA
virginia commonwealth university, richmond, VA, USA

PHP67
D5
IMPACT OF POST-SURGICAL COMPLICATIONS ON HOSPITAL COSTS AND MARGINS
Bao J1, Lavender R2, Chapman R1
1Avalere Health, Washington, DC, USA, 2Edwards Lifesciences, Irvine, CA, USA

PHP68
WITHDRAWN

PHP69
WITHDRAWN

PHP70
D6
WHO IS SPENDING WHERE: ANALYSIS OF HEALTHCARE SPENDING BY MEDICAID AND PRIVATE PAYERS IN MASSACHUSETTS
Olchanski N1, Rane PB1, Cohen JT1, Neumann PJ2
1Center for the Evaluation of Value and Risk in Health,Tufts Medical Center, Boston, MA, USA, 2Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies,Tufts Medical Center, Boston, MA, USA

PHP71
D7
PRODUCTIVITY GROWTH IN CALIFORNIA HOSPITALS FROM 2005 THROUGH 2011
Cheng W, Romley JA
University of Southern California, Los Angeles, CA, USA

PHP72
D8
IMPACT OF THE SHIFT TO MEDICAID MANAGED CARE ON RESOURCE UTILIZATION AND COSTS FOR BENEFICIARIES IN MISSISSIPPI MEDICAID
Ramachandran S1, Banahan III B1, Hardwick SP2, Clark JP2
1University of Mississippi, University, MS, USA, 2Mississippi Division of Medicaid, Jackson, MS, USA

PHP73
D9
PUBLISHED COSTS OF MEDICATION ERRORS LEADING TO PREVENTABLE ADVERSE DRUG EVENTS IN US HOSPITALS
Pan J1, Mays R2, Gill S3, Albert NM4, Patel D2, Stephens J2, Rocha-Cunha C1, Pulgar S1
1Becton Dickinson, Franklin Lakes, NJ, USA, 2Pharmerit International, Bethesda, MD, USA, 3University of Pittsburgh, Pittsburgh, PA, USA, 4Cleveland Clinic, Cleveland, OH, USA

PHP74
D10
THE FINANCIAL IMPACT OF BLOOD SPECIMEN REJECTION DUE TO THE POOR PRE-ANALYTICAL QUALITY IN HEALTHCARE FACILITY IN CHINA
Liu Y1, Ren X2
1Shenyang Pharmaceutical University, Shenyang, China, 2BD China, Shanghai, China

PHP75
D11
REGIONAL VARIATION IN CATASTROPHIC HEALTH CARE SPENDING IN PAKISTAN
Jahangeer RA
Pakistan Institute of Development Economics (PIDE), Islamabad, Pakistan

PHP76
D12
A LITERATURE REVIEW AND MICRO COSTING APPROACH TO DETERMINE THE COST OF ONE HOUR OF OPERATING TIME IN CANADA
Goldstein LJ, Ondrejicka DA
Johnson and Johnson Medical Companies, Markham, ON, Canada

PHP77
D13
CURRENT ESTIMATES OF THE PUBLIC PHARMACEUTICAL EXPENDITURE IN MONGOLIA
Dorj G
Mongolian Univerisity of Medical Sciences, Ulaanbaatar, Mongolia

PHP78
D14
CROSS SECTION ANALYSIS OF MARGINAL NHS EXPENDITURE BY ENGLAND HEALTH AREA
Hernandez-Villafuerte K, Sussex J
Office of Health Economics, London, UK

PHP79
D15
MEDICATION USE SURVEY OF INPATIENTS WITH BASIC MEDICAL INSURANCE FROM 2010 TO 2012
Xiong X1, Li J1, Zhang J1, Ma Y1, Gao SQ2, Yang L2
1China Health Insurance Research Association, Beijing, China, 2Beijing Brainpower Pharma Consulting Co. Ltd, Beijing, China

PHP80
D16
WHICH DISEASES ARE DRIVING THE INCREASE IN SPENDING FOR THE PRIVATELY INSURED POPULATION OF THE US?
Marder WD, Huse DM
Truven Health Analytics, Cambridge, MA, USA

PHP81
E1
ACA'S IMPACT ON MERGERS AND WELLNESS: ASSESSING VALUE FOR MONEY
Vu M1, Lovett AW1, Kelley VP2, Hopper J2, Liu C1
1Mercer University, Atlanta, GA, USA, 2Piedmont Healthcare, Atlanta, GA, USA

PHP82
E2
IMPACT OF CLINICAL AND HEALTH ECONOMIC PUBLICATIONS ON COMMERCIAL SUCCESS OF PHARMACEUTICAL PRODUCTS IN THE U.S
Slejko JF1, Basu A2, Sullivan SD3
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Washington, Seattle, WA, USA, 3University of Washington School of Pharmacy, Seattle, WA, USA

PHP83
E3
PREVALENCE OF MEDICATION USE NOT CAPTURED BY PRESCRIPTION CLAIMS DATABASES – AN ANALYSIS USING 2012 MEDICAL EXPENDITURE PANEL SURVEY DATA
Electricwala B1, Carroll NV2
1Virginia Commonwealth Univeristy, Richmond, VA, USA, 2Virginia Commonwealth University, Richmond, VA, USA

PHP84
E4
IMPROVED HEOR WRITING SKILLS OF KEEN INTEREST TO BIO/PHARMA HEOR DIRECTORS AND MANAGERS
Drake T1, Peeples P2, Smalarz A3, McClain B4
1Global Outcomes Group, Reston, VA, USA, 2HealthEconomics.com, Ponte Vedra Beach, FL, USA, 3Strategic Market Insight, Acton, MA, USA, 4Grapheme Consulting, Greensboro, NC, USA

PHP85
E5
COMMUNICATING RISK OF MEDICATION SIDE EFFECTS: HOW RARE IS ‘RARE' AND HOW LIKELY IS ‘LIKELY'?
Sawant RV, Sansgiry SS
University of Houston, Houston, TX, USA

PHP86
E6
THE NUTRITIONAL STATUS OF ORPHANS AND CHILDREN LEFT WITHOUT PARENTAL CARE IN THE CHILDREN'S HOMES OF THE HEALTH SYSTEM IN KAZAKHSTAN
Turgambayeva A1, Bukeyeva Z1, Suleimenova R1, Syzdykova A2
1Astana Medical University, Astana, Kazakhstan, 2Child-Nutrition Fund, Almaty, Kazakhstan

PHP87
E7
WHAT FACTORS MAKE ECONOMIC EVALUATION MORE VALUABLE AS A SERVICE?
Page K1, Merlo G1, Ratcliffe J2, Halton K1, Graves N1
1Queensland University of Technology, Brisbane, Australia, 2Flinders University, Adelaide, Australia

PHP88
E8
REAL WORLD DATA FOR HEALTH AND TECHNOLOGY ASSESSMENT IN BRAZIL: AN UNMET NEED
Minowa E1, Piedade A1, Julian G2
1Evidências - Kantar Health, Campinas, Brazil, 2Evidências - Kantar Health, São Paulo, Brazil

PHP89
E9
USE OF LOW-COST GENERIC PROGRAMS IN A NATIONALLY REPRESENTATIVE MEDICARE POPULATION AND IMPLICATIONS FOR QUALITY INITIATIVES
Pauly N, Brown J
University of Kentucky, Lexington, KY, USA

PHP90
E10
RELATIONSHIP BETWEEN THE DEVELOPMENT OF ELECTRONIC HEALTH RECORDS AND HOSPITAL ACCREDITATION DECISIONS IN FRANCE: RESULTS FROM THE E-SI (PREPS-SIPS) STUDY
Perrier L1, Havet N2, Durand T1, Caquot N1, Amaz C1, Biron P1, Philip I1
1Cancer Centre Léon Bérard, Lyon, France, 2University Lyon 2, Lyon, France

PHP91
WITHDRAWN

PHP92
E11
SERIOUS ADVERSE DRUG EVENTS REPORTED TO THE FOOD AND DRUG ADMINISTRATION (FDA): ANALYSIS OF THE FDA ADVERSE EVENT REPORTING SYSTEM (FAERS) 2006-2011 DATABASE
Sonawane KB, Hansen RA
Auburn University, Auburn, AL, USA

PHP93
E12
SENSITIVITY, SPECIFICITY AND LEVEL OF AGREEMENT BETWEEN DIFFERENT CRITERIA USED TO DIAGNOSE THE METABOLIC SYNDROME
Bhounsule P1, Peterson AM2
1University of the Sciences in Philadelphia, Philadelphia, PA, USA, 2University of the Sciences, Philadelphia, PA, USA

PHP94
E13
IN THEIR OWN WORDS: SOCIAL LISTENING FOR “REAL-WORLD BENEFITS” FROM PRESCRIPTION AND OTC PRODUCTS
Powell GE, Duke SP, Bell HG, Anderson LS, Metcalf MA
GSK, RTP, NC, USA

PHP95
E14
IS THERE AN ASSOCIATION BETWEEN POTENTIALLY INAPPROPRIATE PRESCRIBING IN THE ELDERLY AND HOSPITALIZATION AND MORTALITY? A LONGITUDINAL, LARGE COHORT STUDY
Vegesna A1, Alcusky MJ1, Keith SW1, Hegarty SE1, Del Canale S2, Lombardi M2, Maio V1
1Thomas Jefferson University, Philadelphia, PA, USA, 2Parma Local Health Authority, Parma, Italy

PHP96
E15
AN INTENSIVE STUDY OF ADVERSE EVENTS IN THE MEDICAL UNIT OF A NIGERIAN TEACHING HOSPITAL
Oreagba IA, Bada SO, Chuka-Ebene V
University of Lagos, Lagos, Nigeria

PHP97
E16
RACIAL/ETHNIC DISPARITIES IN DISABILITY PREVALENCE
Goyat R1, Vyas A2, Sambamoorthi U1
1West Virginia University, Morgantown, WV, USA, 2Rutgers University, Piscataway, NJ, USA

PHP98
F1
COMPARATIVE EFFECTIVENESS RESEARCH (CER) AND ITS EFFECT ON THE HEALTH CARE DECISION-MAKING ENVIRONMENT
Westrich KD
National Pharmaceutical Council, Washington, DC, USA

PHP99
F2
EMERGENCY DISEASE SPECTRUM IN CHINA: BASED ON HOSPITAL DATABASE FROM BEIJING
Liu Y1, Wu J2, Zhang J2
1Peking university, Beijing, China, 2306 hospital of PLA, Beijing, China

PHP100
F3
KEY TRENDS IN HEALTHCARE SPENDING IN BRAZIL IN 2015
Saggia M
Asigma, Sao Paulo, Brazil

PHP101
F4
COMPARATIVE EFFECTIVENESS, APPROVAL RATES AND PRICING OF DRUGS WITH FDA'S BREAKTHROUGH THERAPY DESIGNATIONS
Aggarwal S1, Topaloglu H1, Kumar S2
1NOVEL Health Strategies, Chevy Chase, MD, USA, 2GLOBAL ACCESS Monitor, Bethesda, MD, USA

PHP102
F5
THE VALUE OF OTC MEDICINES IN BRAZILIAN PUBLIC HEALTH SYSTEM (SUS)
Ferreira CN1, Santana CF2, Rufino CS1
1Pfizer Brasil, São Paulo, Brazil, 2Pfizer, São Paulo, Brazil

PHP103
F6
PHYSICIAN PERCEPTION OF PHARMACY ADHERENCE BARRIERS IN A COHORT OF MEDICARE ADVANTAGE PLANS IN TEXAS
Winters A1, Esse T1, Serna O1, Bhansali A2, Sansgiry S3
1Cigna HealthSpring, Houston, TX, USA, 2University of Houston College of Pharmacy, Houston, TX, USA, 3University of Houston, Houston, TX, USA

PHP104
F7
EVALUATING THE OUTCOMES OF A HIGH-RISK MEDICATION INTERVENTION PROGRAM BETWEEN DUAL AND NON-DUAL ELIGIBLE MEDICARE ADVANTAGE BENEFICIARIES
Leung K1, Sendzik J1, Lee GC2
1Anthem, Norfolk, VA, USA, 2The University of Texas at Austin and UT Health Science Center at San Antonio, San Antonio, TX, USA

PHP105
F8
IMPACT OF NEW CHANGES DUE TO AFFORDABLE CARE ACT ON US MARKET ACCESS
Topaloglu H, Aggarwal S
NOVEL Health Strategies, Chevy Chase, MD, USA

PHP106
F9
ARE EU PAYERS ADAPTING BIOSIMILAR PRICING AND REIMBURSEMENT APPROVAL PROCESSES TO OPTIMIZE HEALTHCARE SAVINGS?
Foxon G1, Fox G1, Craddy P2
1Remap Consulting, Cheshire, UK, 2Remap Consulting, Bern, Switzerland

PHP107
F10
THE WHO-CHOICE COST-EFFECTIVENESS THRESHOLD: A COUNTRY-LEVEL ANALYSIS OF CHANGES OVER TIME
Griffiths M, Maruszczak M, Kusel J
Costello Medical Consulting Ltd, Cambridge, UK

PHP108
F11
THE EFFECT OF INNOVATION LAG ON DRUG ACCESS IN TAIWAN
Hsieh C1, Tasi Y1, Chiang Y1, Huang W2
1National Yang-Ming University, Taipei, Taiwan, 2National Yang Ming University, Taipei, Taiwan

PHP109
F12
OVERVIEW AND IMPORTANCE OF NUB PROCESS FOR MARKET ACCESS OF IN-PATIENT DRUGS AND DEVICES IN GERMANY
Aggarwal S1, Kumar S2, Topaloglu H1
1NOVEL Health Strategies, Chevy Chase, MD, USA, 2GLOBAL ACCESS Monitor, Bethesda, MD, USA

PHP110
F13
THE POTENTIAL IMPACT OF PRICE ADJUSTMENTS OF A NEW THERAPY IN GERMANY ON OTHER COUNTRIES: A SIMULATION MODELLING EXERCISE
Stoykova B1, Walzer S2, Dröschel D2, Zah V3
1Daiichi Sankyo Development, Gerard's Cross, UK, 2MArS Market Access & Pricing Strategy GmbH, Weil am Rhein, Germany, 3ZRx Outcomes Research Inc., Belgrade, Serbia and Montenegro

PHP111
F14
CURRENT TRENDS IN US AND EUROPEAN PRICING OF UNIQUE BIOPHARMA PRODUCTS
Bajpai SK1, Shields GE2
1Institute of Pharmaceutical Management, Yardley, PA, USA, 2BresMed, Sheffield, UK

PHP112
F15
WILL FLAT EU PRICING BECOME A REALITY? CONSIDERATIONS FOR THE BIOPHARMA INDUSTRY AND WHETHER FUTURE EU PRICING TRANSPARENCY RULES WILL AFFECT THE CURRENT POSITION
Ranson P1, Hill CA1, Cline H2, Hill CE1, Marshall JD1, Harries M1
1MAP BioPharma Limited, Cambridge, UK, 2Pinsent Masons LLP, London, UK

PHP113
F16
THE VALUE OF NON-RANDOMISED EVIDENCE FOR INFORMING CLINICAL EFFECTIVENESS: AN ASSESSMENT OF HTA REQUIREMENTS AND PUBLISHED GUIDANCE REGARDING THE APPROPRIATENESS OF NON-RANDOMISED DATA
King D, Mitchell S, Dillon R, Lockhart I
Abacus International, Bicester, UK

PHP114
G1
A SURVEY OF ISPOR ATTENDEE VIEWS ON THE USE OF ICER AND ACCEPTABLE ICER THRESHOLDS
Nanavaty M1, Kaura S2, Proach J1, Ramesh V1, Seetasith A1, Khan ZM2
1Market Access Solutions LLC, Raritan, NJ, USA, 2Celgene Corporation, Summit, NJ, USA

PHP115
G2
JAPAN PRICING METHODOLOGY ANALOGUE ASSESSMENT
Park S, Fatoo A, Yampolsky D, Martin de Bustamante M
CBPartners, New York, NY, USA

PHP116
G3
LITERATURE REVIEW OF THE USE OF ICER THRESHOLDS IN HEALTHCARE DECISION-MAKING
Nanavaty M1, Kaura S2, Nyandege A1, Seetasith A1, Khan ZM2
1Market Access Solutions LLC, Raritan, NJ, USA, 2Celgene Corporation, Summit, NJ, USA

PHP117
G4
THE TROUBLE WITH COST-UTILITY HTA BODIES: THEY SHOULD DETERMINE THE PRICE NOT REACT TO IT
Macaulay R
PAREXEL, London, UK

PHP118
WITHDRAWN

PHP119
G5
TRENDS IN BUDGET IMPACT ANALYSIS ACROSS CENTRAL ASIAN COUNTRIES
Kostyuk A1, Akanov A2, Almadiyeva A2
1Kazakh Medical University for Continuing Education, Astana, Kazakhstan, 2Astana Medical University, Astana, Kazakhstan

HEALTH CARE USE & POLICY STUDIES - Health Care Research & Education
PHP120
G6
GENDER DIFFERENCES IN THE USE OF COMPLEMENTARY AND ALTERNATIVE MEDICINE AMONG ADULTS WITH MULTIPLE CHRONIC CONDITIONS
Alwhaibi M, Sambamoorthi U
West Virginia University, Morgantown, WV, USA

PHP121
G7
ATTITUDES TOWARDS COLLABORATION AMONG NURSES AND PHYSICIANS PRACTICING IN NEWLY ESTABLISHED MEDICAL HOMES
Alcusky MJ1, Ferrari L2, Rossi G2, Liu M1, Maio V1
1Thomas Jefferson University, Philadelphia, PA, USA, 2Parma Local Health Authority, Parma, Italy

PHP122
G8
THE CHANGING FACE OF THE COST-UTILITY LITERATURE, 1990–2012
Thorat T1, Shi J1, Saret CJ2, Cohen JT2, Neumann PJ3
1Tufts Medical Center, Boston, MA, USA, 2Center for the Evaluation of Value and Risk in Health,Tufts Medical Center, Boston, MA, USA, 3Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies,Tufts Medical Center, Boston, MA, USA

PHP123
G9
COVERAGE OF MEDICAL DEVICES: IS MEDICARE CONSISTENT WITH PRIVATE PAYERS?
Chenoweth MD1, Chambers J1, Thorat T1, Neumann PJ2
1Tufts Medical Center, Boston, MA, USA, 2Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies,Tufts Medical Center, Boston, MA, USA

PHP124
G10
ENROLLMENT IN HEALTH EXCHANGE PLANS IN 2014: THE IMPACT OF KEY VARIABLES ON UPTAKE OF THIS INNOVATION IN AFFORDABLE HEALTHCARE?
Moore R, Lewis C
Decision Resources Group, Nashville, TN, USA

PHP125
G11
USE OF GLOBAL DATA SETS TO ASSESS INNOVATION LANDSCAPES IN EMERGING MARKETS
Ondere L, Garfield S
GfK Custom Research, Wayland, MA, USA

PHP126
G12
PHARMACY DIRECTORS' PERCEPTIONS OF ADMINISTRATORS' AND HEALTH PROFESSIONALS' ATTITUDES TOWARDS COLLABORATIVE DRUG THERAPY MANAGEMENT (CDTM) IN U.S. HOSPITALS
Mishra P, Thomas III J
Purdue University, West Lafayette, IN, USA

PHP127
G13
HOW MANY OUTPATIENT SURGERY BEDS DO WE NEED?
Wong P, Sommer M, Buhs A
HSHS, Belleville, IL, USA

PHP128
G14
DOES THE OWNERSHIP AND USE OF MOSQUITO TREATED NETS BY HOUSEHOLD MEMBERS DEPEND ON THE LEVEL OF EDUCATION OF THE HEAD OF HOUSEHOLD? CASE STUDY OF WESTERN KENYA
Alvin MM1, Mogere DM2
1Ministry of Health,Kisii Teaching and Referral Hospital, Kisii, Kenya, 2Great Lakes University of Kisumu, Nairobi, Kenya

PHP129
WITHDRAWN

PHP130
G15
GENERIC COMPETITION AND AUTHORIZED GENERICS IN THE UNITED STATES
Moon J1, Nkurunziza J1, Jambi A1, Seoane-Vazquez E1, Qian J2, Hansen RA2
1MCPHS University, Boston, MA, USA, 2Auburn University, Auburn, AL, USA

PHP131
G16
GENERIC MEDICINES-PERCEPTIONS AND ATTITUDES OF FUTURE HEALTHCARE DECISION MAKERS IN SOUTHERN KARNATAKA
Udupa N1, Vohra Y2, Ahmed Z2, Lavu A2, Jain P1
1Manipal University, Manipal, India, 2Manipal College of Pharamaceutical Sciences, Manipal, India

PHP132
G17
PERCEPTIONS AND KNOWLEDGE ON ANTIBIOTIC USE AND RESISTANCE AMONG HIGH SCHOOL STUDENTS AND TEACHERS IN NEW DELHI, INDIA
Kotwani A1, Wattal C2, Siddiqui Z1, Joshi P3
1V. P. Chest Institute, Delhi, India, 2Sir Ganga Ram Hospital, New Delhi, India, 3University of Delhi, Delhi, India

PHP133
G18
GENDER-SPECIFIC SAFETY OUTCOME REPORTS FOR NEW MOLECULAR ENTITY DRUGS
Lee S1, Yoo H2, Kim S2, Koo B2, Lee E2
1Chonnam National University School of Dentistry, Gwangju, South Korea, 2Seoul National University, Seoul, South Korea

PHP134
G19
IMPROVEMENTS IN SELF-REPORTED REAL-WORLD DECISION-MAKING ABILITY AFTER COMPLETION OF A COMPARATIVE EFFECTIVENESS RESEARCH CONTINUING EDUCATION CERTIFICATE
Pickering MK1, Perfetto EM1, Zaghab RW1, Anyanwu C1, Graff JS2, Eichelberger B3
1University of Maryland, School of Pharmacy, Baltimore, MD, USA, 2National Pharmaceutical Council, Washington, DC, USA, 3Academy of Managed Care Pharmacy, Alexandria, VA, USA

PHP135
G20
PERCEPTIONS OF THE ROLES OF PATIENTS AND PAYERS IN PHARMACEUTICAL MARKET ACCESS
Sendyona S1, Choksi P1, Odeyemi IA2, Toumi M3
1Université Claude Bernard Lyon I, Lyon, France, 2Astellas Pharma EMEA, Chertsey, UK, 3Université Aix Marseilles, Marseilles, France

HEALTH CARE USE & POLICY STUDIES - Health Technology Assessment Programs
PHP136
G21
TREND ANALYSIS OF TECHNOLOGY APPRAISAL DECISIONS FROM THE NATIONAL INSTITUTE OF HEALTH AND CARE EXCELLENCE (NICE) – WHAT FACTORS INFLUENCE THE LIKELIHOOD OF RECOMMENDATIONS?
Marshall JD, Hill D, Hill CA, Harries M
MAP BioPharma Limited, Cambridge, UK

PHP137
H1
HAVE CHANGES TO THE SCOTTISH MEDICINES CONSORTIUM (SMC) PROCESS FOLLOWING THE ROUTLEDGE REVIEW REALLY IMPROVED ACCESS TO ORPHAN MEDICATIONS AND WHAT FACTORS INFLUENCE RECOMMENDATIONS?
Marshall JD, Hill D, Hill CA, Harries M
MAP BioPharma Limited, Cambridge, UK

PHP138
H2
TREND ANALYSIS OF SMC DECISIONS – WHAT FACTORS INFLUENCE THE LIKELIHOOD OF POSITIVE, RESTRICTED AND NEGATIVE RECOMMENDATIONS?
Hill D, Marshall JD, Hill CA, Harries M
MAP BioPharma Limited, Cambridge, UK

PHP139
H3
TRENDS IN THE USE OF COST-MINIMIZATION ANALYSIS IN ECONOMIC ASSESSMENTS SUBMITTED TO THE SMC
Marshall JD, Harries M, Hill D, Hill CA
MAP BioPharma Limited, Cambridge, UK

PHP140
H4
ASSESSING THE QUALITY OF HEALTH ECONOMIC EVALUATIONS PUBLISHED IN JAPANESE SETTIGNS: A SYSTEMATIC REVIEW OF 1991-2012 LITERATURE
Sugimoto T1, Kamae I1, Yamabe K2
1The University of Tokyo, Graduate School of Public Policy, Tokyo, Japan, 2The University of Tokyo, Tokyo, Japan

PHP141
H5
ROLE OF INDIRECT COMPARISONS IN THE AMNOG EVALUATION PROCEDURE
Bustamante MM1, Gambari J2
1CBPartners, New York, NY, USA, 2CBPartners, London, UK

PHP142
H6
TREND ANALYSIS OF G-BA DECISIONS – WHAT FACTORS INFLUENCE THE LIKELIHOOD OF RECOMMENDATIONS?
Hill CA, Hill D, Marshall JD, Harries M
MAP BioPharma Limited, Cambridge, UK

PHP143
H7
ANALYSIS OF HEALTH TECHNOLOGY ASSESSMENT REQUIREMENTS IN 7 ASIA OCEANIA COUNTRIES/REGIONS: COMPARISON OF EVIDENTIARY REQUIREMENTS FOR STANDARD AND ORPHAN DRUGS
Knight JM, Campbell DJ, Meyer KL, Clark RS
Xcenda, Palm Harbor, FL, USA

PHP144
H8
TRENDS IN HEALTH TECHNOLOGY ASSESSMENT (HTA) RECOMMENDATIONS FROM THE UK AND GERMANY – A COMPARISON OF G-BA, SMC AND NICE SINGLE TECHNOLOGY APPRAISAL DECISIONS
Hill CA, Hill D, Marshall JD, Harries M
MAP BioPharma Limited, Cambridge, UK

PHP145
H9
USE OF REAL WORLD EVIDENCE IN GERMAN AMNOG APPLICATIONS
Altevers J, Borchert K, Mittendorf T, Braun S
Xcenda GmbH, Hannover, Germany

PHP146
H10
THE VALIDITY OF THE PROPORTIONAL HAZARDS ASSUMPTION FOR THE META-ANALYSIS OF TIME TO EVENT DATA TO SUPPORT SUBMISSIONS TO HEALTH TECHNOLOGY ASSESSMENT (HTA) AUTHORITIES
Batson S, Webb N, Hudson P, Greenall G
Abacus International, Oxfordshire, UK

PHP147
H11
AN ANALYSIS OF RECENT HTA DECISIONS IN TAIWAN AND KOREA: INFLUENCE FROM AUSTRALIA AND THE UK
Sun D1, Duttagupta S1, Yong C2
1CBPartners, New York, NY, USA, 2CB Partners, New York, NY, USA

PHP148
H12
AN ANALYSIS OF NICE RECOMMENDED IN LINE WITH CLINICAL PRACTICE HEALTH TECHNOLOGY ASSESSMENT DECISIONS
O'Neill P1, Chapman AM1, Devlin N1, Duran A2
1Office of Health Economics, London, UK, 2Pfizer Ltd, Surrey, UK

PHP149
H13
A COMPARISON OF G-BA'S ADDITIONAL BENEFIT SCORE TO NICE ICERS
Jaksa A, Liden D, Ho Y
Context Matters, New York, NY, USA

PHP150
H14
PRACTICAL PROBLEMS OF COMPARATOR SELECTION TO ASSESS COST-EFFECTIVENESS OF NEW DRUGS FOR REIMBURSEMENT DECISION: A QUALITATIVE STUDY IN SOUTH KOREA
Kang H1, Lee H1, Cho H2
1Yonsei University, Incheon, South Korea, 2Yonsei University, College of Pharmacy, Yonsei Institute of Pharmaceutical Sciences, Incheon, South Korea

PHP151
H15
BUILDING QUALITY IN HTA PROCESS AND DECISION MAKING: CAN KEY PERFORMANCE MEASURES OF GOOD PRACTICES IN HTA BE IDENTIFIED?
WANG T
CIRS, London, UK

PHP152
H16
HOW ARE TOPICS SELECTED AND PRIORITIZED BY THE NATIONAL INSTITUTE OF HEALTH AND CARE EXCELLENCE (NICE) AND WHAT MIGHT BE THE OPTIONS IF A TECHNOLOGY IS NOT SELECTED?
Ranson P1, Cline H2, Hill CA1, Hill CE1, Marshall JD1, Harries M1
1MAP BioPharma Limited, Cambridge, UK, 2Pinsent Masons LLP, London, UK

PHP153
H17
ACCESS TO MEDICINE, REIMBURSEMENT AND PRICING IN GERMANY: WHAT ARE THE IMPLICATIONS OF AMNOG?
Mueller E, Schmidt E, Schrank L, Neeser K
LASER ANALYTICA, Loerrach, Germany

PHP154
H18
EVALUATING GLOBAL EARLY MARKET ACCESS OPPORTUNITIES FOR INNOVATIVE THERAPIES: FOCUS ON JAPAN, UK AND US
Carr DR, Anastasaki E, Bradshaw SE
Market Access Solutions Ltd, London, UK

PHP155
H19
COMPARISON OF HEALTH TECHNOLOGY ASSESSMENT (HTA) RANKINGS BY GERMAN AND FRENCH HTA AGENCIES
Hu I1, Zheng J2, Hu XH2
1University of Southern California, Los Angeles, CA, USA, 2Celgene Corporation, Summit, NJ, USA

PHP156
H20
HOW DOES A SMALL OR MEDIUM SIZED PHARMACEUTICAL COMPANY PREPARE FOR AND NAVIGATE THE SCOTTISH MARKET?
Marshall JD, Hill D, Hill CA, Harries M
MAP BioPharma Limited, Cambridge, UK

PHP157
H21
PROMOTION OF MOBILE MEDICAL APPS
Kotlo A1, Muragundi PM1, Malini S2, Udupa N1
1Manipal University, Manipal, India, 2MAGNA, Bangalore, India

HEALTH CARE USE & POLICY STUDIES - Patient Registries & Post-Marketing Studies
PHP158
I1
PHYSICIANS' VIEWS ON PHARMA ROLE IN REAL WORLD EVIDENCE GENERATION IN POLAND
Skrzekowska-Baran I1, Wierzbicka N1, Zmiejko S2
1Janssen-Cilag Polska, Warsaw, Poland, 2Sequence HC Partners, Warsaw, Poland

HEALTH CARE USE & POLICY STUDIES - Health Status/Population Health
PHP159
I2
IS SPATIAL SEGREGATION BY INCOME ASSOCIATED WITH SELF-REPORTED DISABILITY IN CHILE? EXPLORATORY ANALYSIS USING A POPULATION-BASED SURVEY
Zitko P1, Cabieses B2
1Complejo Asistencial Barros Luco, Santiago, Chile, 2Universidad del Desarrollo, Santiago, Chile

PHP160
I3
MULTIPLE CHRONIC CONDITIONS AND BMI: POPULATION ESTIMATES FOR HEALTH DECISION MAKING IN PUERTO RICO
Amill A1, Serrano R1, González E2, Pérez-Perdomo R3
1Puerto Rico Department of Health, San Juan, PR, USA, 2Johns Hopkins, Baltimore, MD, USA, 3Centro de Diabetes para Puerto Rico, San juan, PR, USA

PHP161
I4
THE RELATIONSHIP BETWEEN DISABILITY AND MIGRATION STATUS IN CHILE: PRELIMINARY ANALYSIS FROM REPEATED CROSS-SECTIONAL SURVEY
Cabieses B, Delgado I, Bernales M, Obach A
Universidad del Desarrollo, Santiago, Chile

PHP162
I5
SOCIAL AND HEALTH VULNERABILITY OF INTERNATIONAL IMMIGRANTS IN CHILE: PRELIMINARY FINDINGS FROM A SPATIAL ANALYSIS USING 2002-2012 CENSUS DATA
Vasquez A1, Cabieses B2, Aragay M2, McIntyre AM2
1Pontificia Universidad Catolica de Chile, Santiago, Chile, 2Universidad del Desarrollo, Santiago, Chile

PHP163
I6
CHILEAN VALUATION OF THE EQ-5D HEALTH STATES
Zarate V1, Kind P2
1Universidad de los Andes, Santiago, Chile, 2University of Leeds, Leeds, UK

HEALTH CARE USE & POLICY STUDIES - Prescribing Behavior & Treatment Guidelines
PHP164
I7
AN EVALUATION OF THE USE OF ANTIBIOTICS IN A TEACHING HOSPITAL IN BAHAWALPUR
Ahmad M, Bashir A, Farooq Z, Pervaiz F, Akhtar M
The Islamia University of Bahawalpur, Bahawalpur, Pakistan

PHP165
I8
PROSPECTIVE STUDY ON PRESCRIPTION PATTERN IN TERTIARY CARE HOSPITAL IN SOUTH INDIA
Sirisha S1, Goluguri RR1, Varghese A1, Thomas SM1, Naik V2
1karnataka college of pharmacy, bangalore, India, 2Karnataka college of pharmacy, Bangalore, India

PHP166
I9
EVALUATION OF KNOWLEDGE, ATTITUDES, AND PRACTICES OF HEALTHCARE PROVIDERS TOWARDS NUTRITION SUPPORT IN PAKISTAN
Iqbal MS1, Bahari MB2, Iqbal MZ3, Iqbal MW4, Nasir S5
1Faculty of Pharmacy, Bahauddin Zakariya University, Multan, Pakistan. Department of Clinical Pharmacy, Faculty of Pharmacy, MAHSA University, Selangor, Malaysia, 2Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia, 3Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Universiti Sains Malaysia, Pulau Pinang, Malaysia Department of Clinical Pharmacy & Pharmacy Practice, Faculty of Pharmacy, AIMST University, Kedah, Malaysia, 4Faculty of Law, University of Malaya, Kualalumpur, Malaysia, 5Nishtar Hospital, Multan, Pakistan

PHP167
I10
TRENDS IN USE OF HEALTH ECONOMIC EVIDENCE FOR DEVELOPING CLINICAL GUIDELINES
Aggarwal S1, Kumar S2, Topaloglu H1
1NOVEL Health Strategies, Chevy Chase, MD, USA, 2GLOBAL ACCESS Monitor, Bethesda, MD, USA

HEALTH CARE USE & POLICY STUDIES - Quality of Care
PHP168
I11
EFFECTIVENESS OF INTERVENTIONS FOR DRUG PRESCRIBING IMPROVEMENT IN PRIMARY HEALTH CARE
Zavala-González MA, Cabrera-Pivaral CE, Orozco-Valerio MJ
University of Guadalajara, Guadalajara, Mexico

HEALTH CARE USE & POLICY STUDIES - Regulation of Health Care Sector
PHP169
I12
THE ROLE OF VOLUNTARY HEALTH INSURANCE FUNDS IN SELF-CARE IN HUNGARY
Turcsányi K1, Csákvári T1, Boncz I2
1University of Pécs, Zalaegerszeg, Hungary, 2University of Pécs, Pécs, Hungary

PHP170
I13
WHEN CAN PHARMACEUTICAL COMPANIES COMMUNICATE HEALTH ECONOMIC CLAIMS TO PAYERS? 10 CASE STUDIES
Neumann PJ1, Saret CJ2
1Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies,Tufts Medical Center, Boston, MA, USA, 2Center for the Evaluation of Value and Risk in Health,Tufts Medical Center, Boston, MA, USA

PHP171
I14
IMPLEMENTATION OF NICE CLINICAL GUIDELINES (CG) – WHAT CAN BE LEARNED FROM A UK CASE STUDY AND HOW TO ENSURE THAT HEALTH SERVICES DO NOT FALL SHORT OF THEIR OBLIGATIONS
Ranson P1, Cline H2, Hill CA1, Hill CE1, Marshall JD1, Harries M1
1MAP BioPharma Limited, Cambridge, UK, 2Pinsent Masons LLP, London, UK

PHP172
J1
IRRATIONAL DRUG USE PATTERN IN HOSPITALS. A WARNING FOR HEALTH CARE SYSTEM
Umer Jan S
University of Balochistan, Quetta, Pakistan

HEALTH CARE USE & POLICY STUDIES - Risk Sharing/Performance-Based Agreements
PHP173
J2
FORMULARY MANAGEMENT OF BRANDED DRUGS WITH AND WITHOUT BOXED WARNINGS WITHIN THERAPEUTIC CATEGORIES
Branning G1, Schaars R1, Hornung J2, Wick J1, Kuznik A3
1Managed Market Resources, Mount Olive, NJ, USA, 2Managed Markets Insight & Technology, Yardley, PA, USA, 3Celgene Corporation, Warren, NJ, USA

PHP174
J3
KEY MILESTONES OF PUBLIC-PRIVATE PARTNERSHIPS FOR DRUGS IN BRAZIL
Saggia M
Asigma, Sao Paulo, Brazil

PHP175
J4
OUTCOMES-BASED PRICING AND REIMBURSEMENT ARRANGEMENTS FOR PHARMACEUTICAL PRODUCTS IN THE US AND EU-5: PAYER AND MANUFACTURER EXPERIENCE AND OUTLOOK
Nazareth T1, Ko JJ2, Frois C3, Carpenter S3, Demean S3, Wu EQ4, Sasane R1, Navarro R5
1Novartis Pharmaceuticals, East Hanover, NJ, USA, 2Novartis Pharmaceuticals Corporation, Morristown, NJ, USA, 3Analysis Group, Boston, MA, USA, 4Analysis Group, Inc., Boston, MA, USA, 5University of Florida, Gainesville, FL, USA

PHP176
J5
EVALUATION OF A PHARMACEUTICAL RISK-SHARING AGREEMENT WHEN PATIENTS ARE SCREENED FOR THE PROBABILITY OF SUCCESS
Mahjoub R1, Odegaard F2, Zaric GS2
1University of Alberta, Edmonton, AB, Canada, 2Western University, London, ON, Canada

PHP177
J6
CURRENT SITUATION OF THE PUBLIC-PRIVATE PARTNERSHIPS FOR DRUGS IN BRAZIL
Saggia M
Asigma, Sao Paulo, Brazil

HEALTH CARE USE & POLICY STUDIES - Conceptual Papers
PHP178
J7
TWO-PART PRICING FOR PATENT PROTECTED MEDICINES – AN ECONOMIC ANALYSIS FROM A SWEDISH HEALTH CARE PERSPECTIVE
Hertzman PG1, Holm J2
1Health Access Agency, Zurich, Switzerland, 2Lund University, Lund, Sweden

PHP179
J8
INTRODUCTION FOR THE LATEST DEVELOPMENT OF CHINESE PEDIATRIC MEDICINE
Liu M1, Huang L2, Zhao D2, Xu L2
1AstraZeneca(China), Beijing, China, 2Astrazeneca (China), Beijing, China

PHP180
J9
A SYSTEMATIC QUANTITATIVE APPROACH TO INCORPORATING THE PATIENT PERSPECTIVE INTO HEALTH TECHNOLOGY ASSESSMENT DECISION MAKING
Glase KM1, Walters NB1, Stephenson TM1, Vines R2, Millman S3, Rose J4, Fifer S4
1Janssen Australia, Macquarie Park, Australia, 2Rare Cancers Australia, Bowral, Australia, 3Lymphoma Australia, Westlake, Australia, 4Institute for Choice, North Sydney, Australia

PHP181
J10
CROWDSOURCING HEALTHCARE TECHNOLOGY INNOVATION: THE USE OF OPEN COMPETITIONS TO PURSUE NOVEL HEALTHCARE TECHNOLOGY SOLUTIONS
Ko JJ1, Karagiannis TS2, Tran M3, Obi EN4
1Scott & White Health Plan, East Hanover, NJ, USA, 2Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, 3Scott & White Health Plan, Austin, TX, USA, 4Rutgers University, Piscataway, NJ, USA

PHP182
J11
ANALYSIS OF ETHICAL THEORIES AND PRINCIPLES EMBEDDED IN HOLISTIC MCDA: A PRIMER TO ETHICS-BASED APPRAISAL OF VALUE IN HEALTHCARE
Goetghebeur MM1, Wagner M2, Bond K3, Hofmann B4
1LASER Analytica & University of Montreal, Montreal, QC, Canada, 2LASER Analytica, Montreal, QC, Canada, 3Canadian Agency for Drugs and Technologies in Health, Ottawa, ON, Canada, 4Institute of Health and Society, Oslo, Norway

PHP183
J12
WITHDRAWN

PHP184
J13
THE COUNTRY ARCHETYPE MODEL: UNLOCKING THE DOOR TO GLOBAL MARKET ACCESS
Moore R1, Cox J2
1Decision Resources Group, Nashville, TN, USA, 2Decision Resources Group, London, UK

PHP185
J14
A SITUATION ANALYSIS OF HEALTH POLICY AND HEALTH TECHNOLOGY ASSESSMENT IN KAZAKHSTAN
Kostyuk A1, Akanov A2, Karp L2, Nurgozhin T3, Almadiyeva A2
1Kazakh Medical University for Continuing Education, Astana, Kazakhstan, 2Astana Medical University, Astana, Kazakhstan, 3Nazarbayev University, National Laboratory Astana, Astana, Kazakhstan

PHP186
K1
THE EMERGING ROLE OF PATIENT-REPORTED OUTCOMES (PROS) IN CLINICAL TRIALS IN INDIA
BN V1, Naidu M2, Esam H2, Badgujar L2, Kinra G2, Dang A2
1Velammal Medical College Hospital and Research Institute, Madurai, India, 2MarksMan Healthcare Solutions LLP (HEOR and RWE Consulting), Navi Mumbai, India

PHP187
K2
THE PILLARS OF COST-EFFECTIVENESS: A PRACTICAL GUIDELINE FOR NEW TECHNOLOGY COST-EFFECTIVE DECISION-MAKING
Calderón MR
Novartis Pharmaceuticals, Guatemala, Guatemala

PHP188
K3
DEVELOPING HOSPITAL BASED HTA FOR EGYPTIAN CANCER PATIENTS
Abo Taleb AM1, Saad AS2, Kamal KA2, Metry AB3
1WHO, Cairo, Egypt, 2Ain Shams University, Cairo, Egypt, 3Accsight, Cairo, Egypt

PHP189
K4
AUGMENTING THE REGULATORY REQUIREMENTS OF MEDICATION THERAPY MANAGEMENT TO IMPROVE PROGRAM EFFICIENCY AND OUTCOMES
Mbagwu G1, Godley P2
1The University of Texas at Austin, Austin, TX, USA, 2Scott & White Health Plan, Temple, TX, USA

PHP190
K5
COMMERCIAL HEALTH INSURANCE – A NEW POWER TO PUSH CHINA HEALTHCARE REFORM FORWARD?
Ma R, Huang L, Zhao D, Xu L
Astrazeneca (China), Beijing, China

PHP191
K6
PATIENT REGISTRIES IN INDIA – NATIONAL CANCER REGISTRY PROGRAM
Janodia M, Udupa N
Manipal University, Manipal, India

PHP192
K7
HEALTH DATA ENTANGLEMENT AND ARTIFICIAL INTELLIGENCE-BASED ANALYSES TO IMPROVE THE EFFECTIVENESS OF SERVICES AND TACKLE THE HEALTHCARE SPENDING GROWTH
Capone A1, Mennini FS2, Cicchetti A3, Marcellusi A4, Baio G5, Torlone R6, Favato G7
1Kingston University London, Kingston Upon Thames, UK, 2University of Rome «Tor Vergata», Rome, Italy, 3Catholic University of Sacred Heart, Rome, Italy, 4University of Rome “Tor Vergata”, Rome, Italy, 5University College London, London, UK, 6University «Roma 3», Rome, Italy, 7Kingston University London, London, UK

PHP193
WITHDRAWN

PHP194
K8
POPULATION BASED VALUATION OF PRIVATE ANNUITY AND LIFE INSURANCES UNDER TAIWAN'S NATIONAL HEALTH INSURANCE SYSTEM
Hsu WW1, Wu Y1, Yu P1, Hsieh H1, Ho J2
1National Taiwan Ocean University, Keelung, Taiwan, 2Academia Sinica, Taipei, Taiwan

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.